Tumoristatic effects of endostatin in prostate cancer is dependent on androgen receptor status

Prostate

Volumn 69, Issue 10, 2009, Pages 1055-1066

  Isayeva, Tatyana ^a   Moore, Lakisha D ^a   Chanda, Diptiman ^a   Chen, Dongquan ^b   Ponnazhagan, Selvarangan ^a  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Androgen receptor; Anti angiogenesis; Metastasis; Prostate cancer; TRAMP model

Indexed keywords

ANDROGEN RECEPTOR; ENDOSTATIN; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEINASE; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STEROID RECEPTOR COACTIVATOR 1; ANGIOSTATIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR DIFFERENTIATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPARATIVE STUDY; GENETICS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANGIOSTATINS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; ENDOSTATINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 67449152199     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20952     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA,Chinnaiyan AM.Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
3. Stamey TA, Warrington JA, Caldwell MC, Chen Z, Fan Z, Mahadevappa M, McNeal JE, Nolley R, Zhang Z. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001;166: 2171-2177. (Pubitemid 33065250)
4. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002;62:4427-4433. (Pubitemid 34827303)
5. Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, Tsunoda T, Takata R, Kasahara K, Miki T, Fujioka T, Shuin T, Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res 2004;64:5963-5972. (Pubitemid 39129392)
6. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC, Figg WD. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14:209-214.
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
8. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-1203. (Pubitemid 32708670)
9. Kerr DJ. Targeting angiogenesis in cancer: Clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43. (Pubitemid 40812647)
10. Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P, Pow-Sang J. A phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer 2007;59:163-168. (Pubitemid 350230733)
11. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained anti-angiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007;67:5789-5797. (Pubitemid 46985012)
12. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ, Rosen JM. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
13. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMPmodel. Toxicol Pathol 2003;31:31-38. (Pubitemid 36169419)
14. Moore LD, Isayeva T, Siegal GP, Ponnazhagan S. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: Implications for proliferation and migration in vitro and metastasis in vivo. Clin Cancer Res 2008;14:4961-4970.
15. Lin J, Adam RM, Santiestevan E, Freeman MR. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 1999;59:2891-2897. (Pubitemid 29283128)
16. Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci 2004;117: 2037-2049. (Pubitemid 38745137)
17. Fang WB, Ireton RC, Zhuang G, Takahashi T, Reynolds A, Chen J. Overexpression of EPHA2 receptor destabilizes adherens junctions via a RhoA-dependent mechanism. J Cell Sci 2008;121: 358-368. (Pubitemid 351356707)
18. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008;14:3362-3366.
19. Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, Ellis LM. Endoglin (CD105):A marker of tumor vasculature and potential target for therapy. Clin Cancer Res 2008;14:1931-1937. (Pubitemid 351551101)
20. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995; 9:726-735.
21. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40.
22. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912.
23. Lee FS, Peters RT, Dang LC, Maniatis T. MEKK1 activates both IkappaB kinase alpha and IkappaB kinase beta. Proc Natl Acad Sci USA 1998;95:9319-9324. (Pubitemid 28506229)
24. Nemoto S, DiDonato JA, Lin A. Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase. Mol Cell Biol 1998; 18:7336-7343. (Pubitemid 28533053)
25. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin α5β1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002;62:5580-5589.
26. Thompson TC, Timme TL, Li L, Goltsov A. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999;4:233-237. (Pubitemid 29424486)
27. Bartz R, Zhou J, Hsieh JT, Ying Y, Li W, Liu P. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo. Int J Cancer 2008;122:520-525. (Pubitemid 350308942)
28. Tahir SA, Yang G, Goltsov AA, Watanabe M, Tabata K, Addai J, Fattah el MA, Kadmon D, Thompson TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008;68:731-739.
29. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-225. (Pubitemid 29068531)
30. Somlyo AV, Phelps C, Dipierro C, Eto M, Read P, Barrett M, Gibson JJ, Burnitz MC, Myers C, Somlyo AP. Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB J 2003;17:223-234. (Pubitemid 36164392)
31. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285. (Pubitemid 28015876)
32. Thomas JP, Arzoomanian RZ, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller JH, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-231. (Pubitemid 46606150)
33. Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol 2006;24:3555-3561. (Pubitemid 46630526)
34. Ghosh PM, Malik S, Bedolla R, Kreisberg JI. Akt in prostate cancer: Possible role in androgen-independence. Curr Drug Metab 2003;4:487-496. (Pubitemid 37536869)
35. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERKMAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118:3051-3064.
36. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004;64:7156-7168. (Pubitemid 39331031)
37. Linja MJ, Porkka KP, KangZ, Savinainen KJ, Jänne OA,Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T. Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 2004;10:1032-1040. (Pubitemid 38202234)
38. Léotoing L, Manin M, Monté D, Baron S, Communal Y, Lours C, Veyssière G, Morel L, Beaudoin C. Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: Amolecular switch for epithelial cell differentiation. J Mol Endocrinol 2007;39:151-162. (Pubitemid 47337873)
39. Uzgare AR, Isaacs JT. Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004;64:6190-6199. (Pubitemid 39129421)
40. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007;67:6854-6862.
41. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7:591-604. (Pubitemid 47358145)
42. Ridley AJ, Comoglio PM, Hall A. Regulation of scatter factor/ hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol Cell Biol 1995;15:1110-1122.
43. Nobes CD, Hall A. Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 1999;144:1235-1244. (Pubitemid 29157301)
44. Santos MF, McCormack SA, Guo Z, Okolicany J, Zheng Y, Johnson LR, Tigyi G. Rho proteins play a critical role in cell migration during the early phase of mucosal restitution. J Clin Invest 1997;100:216-225. (Pubitemid 27311260)
45. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J. Expression of ras oncogene p21 in prostate cancer. N Engl J Med 1986;314:133-137. (Pubitemid 16183168)
46. Agnantis NJ, Constantinidou AE, Papaevagelou M, Apostolikas N. Comparative immunohistochemical study of ras-p21 oncoprotein in adenomatous hyperplasia and adenocarcinoma of the prostate gland. Anticancer Res 1994;14:2135-2140.
47. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, Han L, Han K, DiGregorio GB, Katzenellenbogen JA, Katzenellenbogen BS, Roberson PK, Weinstein RS, Jilka RL, Manolagas SC. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 2001;104:719-730. (Pubitemid 32241022)
48. Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O'Brien CA, Plotkin L, Fu Q, Mancino AT, Wen Y, Vertino AM, Powers CC, Stewart SA, Ebert R, Parfitt AM, Weinstein RS, Jilka RL, Manolagas SC. Reversal of bone loss in mice by non-genotropic signaling of sex steroids. Science 2002;298:843-846. (Pubitemid 35231540)